Justin Puckett
Research Subjects
Research Interests
Justin Puckett has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Sachin Kamal-Bahl
COVIA Health Solutions, Lansdale, PA 19446, USA
6 shared publications - Scott F. Huntington
Yale University, New Haven, CT
4 shared publications Jalpa A. Doshi
Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
2 shared publications- Jalpa A. Doshi
University of Pennsylvania, Philadelphia, PA
2 shared publications - Katherine Elizabeth Ryland
Merck & Co., Inc
2 shared publications Monika Raut
Merck & Co, Inc, Rahway, NJ
2 shared publications
Latest Publications
- 4 June 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (10) , e350-e358.e1
Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
- 4 June 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (10) , e350-e358.e1
Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
- Open Access
- 9 February 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (5) , e181-e190
Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting
- 9 February 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (5) , e181-e190
Open AccessReal-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting
- Open Access
- 1 January 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (2) , e6953
Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia
Background: The first‐generation BTK inhibitor ibrutinib is a standard‐of‐care therapy in the treatment of chronic lymphocytic leukemia (CLL) despite potential side effects that often lead to discontinuation.Methods: This study used 2013–2019 claims data to describe the incidence rate of adverse events (AEs) among elderly Medicare beneficiaries newly initiating ibrutinib for CLL.Results: The final sample contained 11,870 Medicare beneficiaries with CLL (mean age 77.2) newly initiating ibrutinib, of whom 65.2% discontinued over mean follow‐up of 2.3 years. The overall incidence rate of AEs was 62.5 per 1000 patient‐months for all discontinuers and 32.9 per 1000 patient‐months for non‐discontinuers. Discontinuers had a higher incidence rate of AEs per 1000 patient‐months compared with non‐discontinuers for all AEs examined, including infection (22.8 vs. 14.5), atrial fibrillation (15.1 vs. 7.0), anemia (21.9 vs. 14.5), and arthralgia/myalgia (19.5 vs. 13.6).Conclusion: In this first real‐world study of a national sample of elderly US patients treated with ibrutinib, we found a clear unmet need for improved management of ibrutinib‐related AEs and/or new treatments to improve real‐world outcomes in patients with CLL.
- 1 January 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (2) , e6953
Open AccessReal‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia
Background: The first‐generation BTK inhibitor ibrutinib is a standard‐of‐care therapy in the treatment of chronic lymphocytic leukemia (CLL) despite potential side effects that often lead to discontinuation.Methods: This study used 2013–2019 claims data to describe the incidence rate of adverse events (AEs) among elderly Medicare beneficiaries newly initiating ibrutinib for CLL.Results: The final sample contained 11,870 Medicare beneficiaries with CLL (mean age 77.2) newly initiating ibrutinib, of whom 65.2% discontinued over mean follow‐up of 2.3 years. The overall incidence rate of AEs was 62.5 per 1000 patient‐months for all discontinuers and 32.9 per 1000 patient‐months for non‐discontinuers. Discontinuers had a higher incidence rate of AEs per 1000 patient‐months compared with non‐discontinuers for all AEs examined, including infection (22.8 vs. 14.5), atrial fibrillation (15.1 vs. 7.0), anemia (21.9 vs. 14.5), and arthralgia/myalgia (19.5 vs. 13.6).Conclusion: In this first real‐world study of a national sample of elderly US patients treated with ibrutinib, we found a clear unmet need for improved management of ibrutinib‐related AEs and/or new treatments to improve real‐world outcomes in patients with CLL.
- Open Access
- 5 December 2023
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (6) , 317-328
Real-World Treatment Patterns, Survival, Health Resource use and Costs Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma
Aim: To examine real-world treatment patterns, survival, healthcare resource use and costs in elderly Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL). Methods: 11,880 Medicare pat... Plain language summary – Older patients with DLBCL need more effective treatments Diffuse large B-cell lymphoma (DLBCL) is the most common form of Non-Hodgkin lymphoma, and it becomes more common w... Tweetable abstract A real-world analysis of nearly 12,000 elderly patients with DLBCL observed high rates of hospitalization and hospice use, poor overall survival in later lines of therapy and sub...
- 5 December 2023
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (6) , 317-328
Open AccessReal-World Treatment Patterns, Survival, Health Resource use and Costs Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma
Aim: To examine real-world treatment patterns, survival, healthcare resource use and costs in elderly Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL). Methods: 11,880 Medicare pat... Plain language summary – Older patients with DLBCL need more effective treatments Diffuse large B-cell lymphoma (DLBCL) is the most common form of Non-Hodgkin lymphoma, and it becomes more common w... Tweetable abstract A real-world analysis of nearly 12,000 elderly patients with DLBCL observed high rates of hospitalization and hospice use, poor overall survival in later lines of therapy and sub...
- Open Access
- 27 May 2022
- Published by Taylor & Francis in Immunotherapy
- Vol. 14 (9) , 741-753
Barriers and Solutions to Improve Access for Chimeric Antigen Receptor Therapies
Chimeric antigen receptor T cells are a potentially curative new therapeutic option, but access challenges remain. The limited number of certified treatment centers and the need to travel to these ... Plain language summary Chimeric antigen receptor T cells are a new type of cancer treatment where the cells from a patient’s own blood are changed in the laboratory and injected back into the patie... Tweetable abstract Access barriers to #CART #celltherapy exist from the perspective of patients, providers and manufacturers, but ongoing and future strategies can alleviate these barriers.
- 27 May 2022
- Published by Taylor & Francis in Immunotherapy
- Vol. 14 (9) , 741-753
Open AccessBarriers and Solutions to Improve Access for Chimeric Antigen Receptor Therapies
Chimeric antigen receptor T cells are a potentially curative new therapeutic option, but access challenges remain. The limited number of certified treatment centers and the need to travel to these ... Plain language summary Chimeric antigen receptor T cells are a new type of cancer treatment where the cells from a patient’s own blood are changed in the laboratory and injected back into the patie... Tweetable abstract Access barriers to #CART #celltherapy exist from the perspective of patients, providers and manufacturers, but ongoing and future strategies can alleviate these barriers.
- 1 March 2022
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 28 (3) , 362-368
Valuing treatment in oncology: embracing a broader notion of value
Over the past decade, we have witnessed unprecedented, groundbreaking innovation in pharmaceuticals. This has been particularly true in oncology, where new therapies have increased survival and at ...
- 1 March 2022
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 28 (3) , 362-368
Valuing treatment in oncology: embracing a broader notion of value
Over the past decade, we have witnessed unprecedented, groundbreaking innovation in pharmaceuticals. This has been particularly true in oncology, where new therapies have increased survival and at ...
- Open Access
- 1 February 2020
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (2) , 507-515.e10
Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population
- 1 February 2020
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (2) , 507-515.e10
Open AccessOmalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population